ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC

Authors:
  • FRFrancesca Ruzzi
    Francesca Ruzzi
  • SAStefania Angelicola
    Stefania Angelicola
  • LLLorena Landuzzi
    Lorena Landuzzi
  • ENElena Nironi
    Elena Nironi
  • MSMaria Sofia Semprini
    Maria Sofia Semprini
  • LSLaura Scalambra
    Laura Scalambra
  • AAAnnalisa Altimari
    Annalisa Altimari
  • EGElisa Gruppioni
    Elisa Gruppioni
  • MFMichelangelo Fiorentino
    Michelangelo Fiorentino
  • FGFrancesca Giunchi
    Francesca Giunchi
  • MFManuela Ferracin
    Manuela Ferracin

Abstract
Original Article ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC Francesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, Elena Nironi, Maria So a Semprini, Laura Scalambra, Annalisa Altimari, Elisa Gruppioni, Michelangelo Fiorentino, Francesca Giunchi, Manuela Ferracin, Annalisa Astol, Valentina Indio, Andrea Ardizzoni, Francesco Gelsomino, Patrizia Nanni, Pier-Luigi Lollini, Arianna Palladini

This publication has 38 references indexed in Scilit: